Collagen synthesis machinery and fibroblast activation markers

Collagen synthesis machinery and fibroblast activation markers represent a broad functional category of proteins rather than a single therapeutic target. This group encompasses the enzymatic tools required for collagen production and cross-linking, such as prolyl 4-hydroxylase and lysyl oxidase (LOX), as well as specific markers that denote the transition of quiescent fibroblasts into secretory myofibroblasts, such as alpha-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP) (Source: PMID: 30272674, PMID: 29107503). In healthy tissue, these components are essential for wound healing and structural integrity; however, their chronic overactivation is a hallmark of pathological fibrosis and the supportive stroma of solid tumors (Source: PMID: 24560522). Therapeutic strategies often focus on inhibiting the signaling pathways that drive fibroblast activation or directly targeting the enzymes responsible for excessive extracellular matrix deposition to treat conditions like idiopathic pulmonary fibrosis and various cancers (Source: NIH, PubChem).

Other names

Fibrotic signaling pathwaysMyofibroblast activation markersExtracellular matrix remodeling components

Drugs targeting these components typically act by inhibiting tyrosine kinases involved in fibroblast signaling, blocking the enzymatic cross-linking of collagen, or depleting activated myofibroblasts through antibody-dependent cellular cytotoxicity.